Coagulopathy in COVID-19
Hemostatic derangement is a hallmark in severe COVID-19. Markedly elevation of D-dimer and fibrinogen degradation product levels were observed in patients with severe COVID-19 higher and 71.4% of nonsurvivors met the International Society of Thrombosis and Haemostasis criteria of disseminated intrav...
Main Authors: | Ka U Lio, Parth Rali |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Lung India |
Subjects: | |
Online Access: | http://www.lungindia.com/article.asp?issn=0970-2113;year=2021;volume=38;issue=7;spage=53;epage=57;aulast=Lio |
Similar Items
-
Proposal of the Definition for COVID-19-Associated Coagulopathy
by: Toshiaki Iba, et al.
Published: (2021-01-01) -
Characteristics and treatment of coagulopathy associated with COVID-19
by: Miljić Predrag
Published: (2021-01-01) -
The Coagulopathy Bleeding in Disseminated Intravascular Coagulation. Therapy by Heparin and Treatment Plasmapheresis
by: Kurgan M., et al.
Published: (2015-12-01) -
COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU
by: Runhui Zheng, et al.
Published: (2021-02-01) -
Management Strategies in Septic Coagulopathy: A Review of the Current Literature
by: Piotr F. Czempik, et al.
Published: (2023-01-01)